Media

Radionuclide Targeted Treatment in Progressing Metastatic Prostate Cancer - Michael Hofman

Details
PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 1 15 minutes: Radionuclide Targeted Treatment in Progressing Metastatic Prostate Cancer - Presented by Michael Hofman, MBBS (Hons), FRACP, FAANMS, FICIS 20 minutes: Discussion Moderators Phillip J. Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS Biographies: Professor Michael Hofman, MBBS (Hons), FRACP, FAANMS, FIC...

PSMA-PET Imaging in Prostate Cancer & PSMA and A Therapeutic Target in Prostate Cancers - Thomas Hope and Johannas Czernin

Details
PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 2 12 minutes: PSMA-PET Diagnostic Imaging in Prostate Cancer - Presented by Thomas Hope, MD Module 3 16 minutes: PSMA as a Therapeutic Target in Progressing Prostate Cancer - Presented by Johannes Czernin, MD 22 minutes: Discussion moderators Phillip Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS Biographies: Joha...

PSMA-directed Therapy - Scott Tagawa and Michael Morris

Details
PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 4 10 minutes: Treatment considerations following 177Lu-PSMA - Presented by Scott T. Tagawa, MD, MS, FACP 17 minutes: PSMA Imaging: A Necessary Gateway for PSMA-Directed Therapy? - Presented by Michael J. Morris, MD 24 minutes: Discussion Moderators Phillip J. Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS Biograph...

PSMA Targeted Radiopharmaceuticals in Prostate Cancer: Introducing the Pivotal Phase III VISION Trial - Oliver Sartor

Details
PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 5 12 minutes: PSMA Targeted Radiopharmaceuticals in Prostate Cancer: Introducing the Pivotal Phase III VISION Trial - Presented by Oliver Sartor, MD 11 minutes: Discussion Moderators Phillip J. Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS Biographies: Oliver Sartor, M.D. C.E. and Bernadine Laborde Professor of C...

Precision Medicine: RadioIsotopes Targeted Therapies in Cancer - Stefano Fanti

Details
PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 6 14 minutes: Precision Medicine: RadioIsotopes Targeted Therapies in Cancer - Presented by Stefano Fanti, MD 15 minutes: Discussion Moderators Phillip J. Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS Biographies: Stefano Fanti, MD Nuclear Medicine Physician, Director of the Nuclear Medicine Division and PET Unit...

Academic and Community Practice Perspectives on Integrating PSMA Lutetium in the Clinic: Lessons Learned from Radium-223 Experience - Oliver Sartor and Nicholas Vogelzang

Details
PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 7 9 minutes: Academic Practice Perspectives on Integrating PSMA Lu-177 into Clinical Practice: Lessons Learned from Radium-223 and More - Presented by Oliver Sartor, MD 6 minutes: Practice Patterns in a Community Medical Oncology Applied to Lutetium: Parallels between lutetium and operationalizing radium-223 - Presented by Ni...

Blue Light Cystoscopy with Cysview®: Tips and Tricks - Anne Schuckman

Details
Anne Schuckman, MD, MBBS, presents a summary of her plenary session presentation from the AUA 2020 live virtual conference on benefits of Blue Light Cystoscopy (BLC ® ) with Cysview ® , in a conversation with Ashish Kamat, MD. Dr. Schuckman details how Cysview can be used to visualize bladder tumors and highlights benefits arising from this technique including an increased ability to resect the tu...

The RESECT Study: Improving Quality in TURBT Surgery - Veeru Kasivisvanathan

Details
Ashish Kamat is joined by Veeru Kasivisvanathan, Kevin Gallagher, and Nikita Bhatt — members of the global research group British Urology Researchers in Surgical Training (BURST) — discussing the global RESECT study. Transurethral REsection and Single instillation intravesical chemotherapy Evaluation in bladder Cancer Treatment (RESECT) Improving quality in TURBT surgery. The RESECT study investig...

Neoadjuvant Immune-Checkpoint Inhibition Vs. Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Bladder Cancer (MIBC) - Andrea Necchi and Petros Grivas

Details
Ashish M. Kamat, MD, MBBS moderates a debate between Andrea Necchi, MD, and Petros Grivas, MD, PhD, on current and emerging treatment options for muscle-invasive bladder cancer. Dr. Necchi argues on the side of immunotherapy before radical cystectomy, reviewing the PURE-01 study of pembrolizumab and the similarly-designed ABACUS study of atezolizumab. He notes that these studies reveal the need fo...

ARAMIS Trial Demonstrates Significant Improvement in Overall Survival in nmCRPC - Neal Shore

Details
Following a presentation at the ASCO 2020 Annual Meeting, Neal Shore discusses the results of the phase III ARAMIS trial which randomized over 1,500 patients with non-metastatic castration-resistant prostate cancer to 600 mg of darolutamide orally twice daily with ADT, versus a placebo-controlled combination with ADT. The study had a composite endpoint of overall survival and radiographic progress...